Vyant Bio Announces One-for-Five Reverse Stock Split
01 nov. 2022 08h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
27 oct. 2022 17h10 HE
|
Vyant Bio, Inc.
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyant...
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
24 oct. 2022 16h15 HE
|
Vyant Bio, Inc.
-To Discuss its Novel Drug Discovery Platform that is Accelerating the Process of Finding Cures for Neurogenerative Diseases CHERRY HILL, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....
Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022
01 sept. 2022 08h00 HE
|
Vyant Bio, Inc.
-Invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ CHERRY HILL, N.J., Sept. 01,...
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment Conference
31 août 2022 08h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights
22 août 2022 16h10 HE
|
Vyant Bio, Inc.
Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into...
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
19 août 2022 09h29 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
15 août 2022 08h05 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
11 août 2022 08h00 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
01 juin 2022 18h05 HE
|
Vyant Bio, Inc.
CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...